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Abstract  Folic  acid  and  cobalamin  are  B-group  vitamins  that  play  an  essential  role  in  many
cellular processes.  Deﬁciency  in  one  or  both  of  these  vitamins  causes  megaloblastic  anaemia,  a
disease characterized  by  the  presence  of  megaloblasts.  Megaloblasts  occur  when  inhibition  of
DNA synthesis  causes  asynchronous  maturation  between  the  nucleus  and  the  cytoplasm.  Clinical
manifestations  are  similar  to  those  of  other  types  of  anaemia,  with  the  exception  of  cobalamin
deﬁciency megaloblastic  anaemia,  which  presents  distinctive  neurological  symptoms.  An  under-
standing of  the  metabolism  of  these  vitamins  will  enable  clinicians  to  make  the  best  use  and
interpretation  of  laboratory  studies  and  monitor  therapeutic  strategies,  which  consist  mainly
of administering  supplements  to  restore  body  reserves.
© 2015  Published  by  Masson  Doyma  México  S.A.  on  behalf  of  Sociedad  Médica  del  Hospital
General  de  México.
PALABRAS  CLAVE
Anemia
Anemias  megaloblásticas:  Metabolismodelácidofólico  y  vitamina  B12megaloblástica; Resumen  Anemias  megaloblásticas:  metabolismo  del  ácido  fólico  y  vitamina  B12  El  ácido
itaminas  del  complejo  B,  indispensables  para  un  número  importante
déﬁcit  de  una  o  ambas  vitaminas  ocasiona  anaemia  megaloblás-
do  por  la  presencia  de  megaloblastos,  resultado  de  la  asincronía
núcleo  y  el  citoplasma  del  eritrocito  debido  a  la  alteración  en  la
staciones  clínicas  son  similares  a  otras  anemias,  salvo  la  anaemiaDeﬁciencia  de
vitamina  B  12;
Ácido  fólico;
Megaloblastos
fólico y  la  cobalamina  son  v
de procesos  celulares.  El  
tica, síndrome  caracteriza
de la  maduración  entre  el  
síntesis de  ADN.  Las  manife∗ Corresponding author at: Dr. Balmis 148, Col. Doctores, C.P. 06726 Mexico City, Mexico.
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megaloblástica  ocasionada  por  déﬁcit  de  cobalamina  que  presenta  alteraciones  neurológicas
de forma  distintiva.  Es  importante  conocer  el  metabolismo  de  las  vitaminas  en  cuestión  para
un correcto  uso  e  interpretación  de  los  estudios  de  laboratorio,  así  como  para  el  monitoreo  de
la terapéutica,  basada  esencialmente  en  reponer  el  déﬁcit  y  restaurar  las  reservas  corporales.
© 2015  Publicado  por  Masson  Doyma  México  S.A.  en  nombre  de  Sociedad  Médica  del  Hospital
General de  México.
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gackground
he  discovery  of  megaloblastic  anaemia  and  its  aetiology
as  the  result  of  the  efforts  of  many  different  medical
esearchers.  It  was  ﬁrst  characterized  by  Addison  in  1849
s  anaemia,  general  languor  and  debility.1 Osler  and  Gard-
er  in  1877  noted  the  association  with  neuropathy,  and  10
ears  later  Lichtheim  documented  myelopathy.  Megaloblasts
ere  identiﬁed  for  the  ﬁrst  time  by  Ehrlich  in  1880.  In  1920,
bnormalities  in  white  blood  cells  were  described.  In  1926,
inot  and  Murphy  showed  that  the  disease  could  be  reversed
y  the  intake  of  large  quantities  of  liver.2 Three  years  later,
astle  established  that  gastric  acid  contains  an  ‘‘intrinsic
actor’’  that  combines  with  an  ‘‘extrinsic  factor’’  to  allow
his  latter  to  be  absorbed.3 Hodgkin  later  identiﬁed  the
tructure  of  vitamin  B12,  for  which  he  received  the  Nobel
rize.4 Years  later,  in  1948,  Herbert  discovered  the  structure
f  folic  acid  and  described  its  association  with  the  aetiology
f  megaloblastic  anaemia.5
eﬁnition
egaloblastic  anaemia  is  a  general  term  used  to  describe
 group  of  anaemias  caused  by  impaired  DNA  synthe-
is.  It  is  characterized  by  abnormal  ﬁndings  in  peripheral
lood  smear  (macroovalocytes)  and  bone  marrow  samples
megaloblastic  hyperplasia).  Megaloblasts,  the  hallmark  of
hese  anaemias,  are  caused  by  asynchronous  maturation
etween  the  nucleus  and  the  cytoplasm  due  to  DNA  synthesis
mpairment.6--8
olic acid metabolism
olic  acid,  also  known  as  pteroyl-glutamate  or  pteroylglu-
amic  acid,  is  made  up  of:  (1)  pteroic  acid;  and  (2)  l-glutamic
cid  (one  or  more  strands)  (see  Fig.  1).8,9
The  functional  form  of  folate  is  tetrahydrofolic  acid.  The
ain  dietary  sources  of  folic  acid  are  green  vegetables,  such
s  asparagus,  broccoli,  spinach  and  lettuce.  It  is  also  found
n  fruit,  such  as  lemons,  oranges,  bananas  and  melons,  and  in
ereals,  grains,  nuts,  beans,  beef,  ﬁsh,  liver  and  kidneys.6
rolonged  storage  or  over-cooking  in  abundant  water  can
igniﬁcantly  reduce  the  folate  content  of  food.10
Daily  adult  requirements  of  folic  acid  range  from  50
o  100  mcg.  The  recommended  dietary  allowance  (RDA)
hown  in  Table  1,  however,  is  far  higher  than  the  mini-
um  requirement.  This  is  because  the  bioavailability  of  folic
cid  depends  on  hydrolysation  of  the  polyglutamate  form  of
m
t
dolate  to  its  monoglutamate  form  to  facilitate  absorption
cross  the  small  intestine.11
The  body  stores  around  5 mg  of  folate  for  between  3  and
 months.  Folate  is  primarily  stored  in  the  liver.12
Folic  acid  is  mainly  absorbed  in  the  jejunum  by  means
f  passive  transport  following  the  concentration  gradient,
nd  by  means  of  active  transport  when  folate  binds  to
educed-folate  transporter  1  and  2  (RFT-1  and  RFT-2)  and
olate  binding  protein  (FBP).  Folic  acid  is  also  absorbed
n  the  ilium,  solely  by  passive  transport.12--14 Folate,  in
ither  its  monoglutamate  or  reduced  monoglutamate  form,
s  absorbed  in  a  neutral  pH  environment  (pH  7.4)  facili-
ated  by  neutralization  of  the  acid  gastric  environment  by
lkaline  pancreatic  juices.14 One  of  2  enzymes,  glutamate
arboxypeptidase  or  polyglutamate  hydrolase,  are  needed
o  hydrolyse  folic  acid  polyglutamate  (the  form  in  which  it
s  found  in  food)  to  its  monoglutamate  form.  These  enzymes
re  found  on  the  luminal  surface  of  the  jejunum  and
leum.13,14
Once  taken  up  by  the  enterocyte,  the  enzyme  dihy-
rofolate  reductase  mediates  the  conversion  of  folic  acid
o  methyltetrahydrofolate  through  a two-step  reaction.
he  folate  then  exits  the  enterocyte  via  the  basolateral
embrane  and  is  either  taken  into  the  systemic  circulation
r  the  enterohepatic  cycle  (liver,  bile  acids,  intestine).  In
he  systemic  circulation,  66%  binds  to  albumin,  33%  remains
ree,  and  a  small  amount  (1%)  binds  to  FBP.  This  is  how  it
s  transported  to  the  cells  where  it  will  be  used.  It  enters
he  cells  either  by  binding  to  RTF-1  or  RTF-2  or  to  folate
eceptor  1  (alpha)  or  2  (beta).  Intracellular  folate  transport
s  mediated  by  clathrin-mediated  endocytosis.  Once  inside
he  cell  (methyltetrahydrofolate),  it  must  be  demethylated
o  become  tetrahydrofolate  (functional  folate  that  can
ccept  glutamic  acid  chains;  these  in  turn  prevent  it  from
xiting  the  cell,  in  other  words,  they  ‘‘anchor’’  it  inside
he  cell).13,15
Excess  intracellular  folic  acid  can  pass  into  the  blood
tream  and  then  be  ﬁltered  through  the  glomerulus,
ecreted  into  the  proximal  tubule,  and  eliminated  in  the
rine  at  a rate  of  2--5  mcg/day.16
The  biological  functions  of  folic  acid  include:  serine-
lycine  conversion,  histidine  catabolism,  purine  synthe-
is,  and  more  importantly,  thymidylate  and  methionine
ynthesis.17
In  thymidylate  synthesis,  folic  acid  carries  one-carbon
roups.  Thymidylate  is  synthesized  from  deoxyuridine
onophosphate  (dUMP)  and  methylenetetrahydrofolate  by
hymidylate  synthase,  which  converts  these  elements  into
ihydrofolate  and  thymidylate.  Thymidylate,  or  thymine,  is
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which  it  is  released  by  the  action  of  gastric  acid  and
pepsin  and  rapidly  taken  up  by  TC  I,  which  carries  it  to
the  duodenum.
Table  1  Recommended  dietary  allowance  of  folic  acid  and
cobalamin  by  age  and  sex.
Patient  population  Folic  acid
(mcg)
Vitamin  B12
(mcg)
Adults,  including  women
of child  bearing  age
400  2Figure  1  Chemical  structure
one  of  the  4  pyrimidine  bases  of  DNA,  and  differentiates  DNA
from  RNA  (which  includes  thymine  instead  of  uracil).  In  the
absence  of  thymine,  uracil  is  incorporated,  thereby  altering
DNA  synthesis.9,17
Metabolism of vitamin B12
The  chemical  structure  of  cobalamin  is  shown  in  Fig.  1.  Note
the  presence  of  1  cobalt  atom  and  4  pyrole  rings  in  the  cen-
tre  of  the  corrin  ring.  Cobalamin  is  given  different  names,
depending  on  the  radical  to  which  it  is  bound.  When  it  binds
to  a  cyano  radical,  it  is  called  cyanocobalamin  or  vitamin
B12,  a  highly  stable  compound.  Other  functional  forms  of
cobalamin  include  adenosylcobalamin  (adenosyl  radical)  and
methylcobalamin  (methyl).
The  main  dietary  sources  of  vitamin  B12  are  animal  foods,
such  as  beef,  liver,  ﬁsh,  and  dairy  products.  It  is  also  found  in
some  animals  that  ingest  cobalamin-synthesizing  bacteria,
such  as  ruminants  and  oysters.  Plant  foods  do  not  contain
cobalamin.6,8
The  recommended  dietary  allowance  of  vitamin  B12  is
shown  in  Table  1.  It  is  important  to  note  that  the  recom-
mended  intake  reported  in  the  literature  ranges  from  2  to
5  mcg/day.9,11
The  body  stores  between  2  to  5  mg  of  vitamin  B12  for
between  3  and  4  months.  Like  folic  acid,  it  is  mainly  stored
in  the  liver.6,12,18
Cobalamin  absorption  in  the  ileum  is  mediated  by  a
receptor  called  cubilin  using  a  calcium-dependent  passive
transport  mechanism.  The  cubilin  receptor  is  actually  a  com-
plex  formed  of  cubilin  and  2  proteins  --  megalin  and  AMN  (the
product  of  the  amnionless  gene,  also  involved  in  the  pro-
duction  of  amnion).  It  has  a  molecular  weight  of  460  kDa,
and  is  also  found  in  the  proximal  tubule,  where  it  medi-
ates  absorption  of  cobalamin  itself.19 Absorption  occurs  in
an  acidic  environment  (pH  5.4).20 There  are  3  cobalamin-
binding  proteins,  which  are  also  called  cobalophilins;  only  1
of  these  is  a  carrier:lic  acid  and  cyanocobalamin.
 Transcobalamin  I  (TC  I).  Also  known  as  haptocorrin  or
R  protein.  It  is  found  in  mature  granulocytes  and  mono-
cytes  and  also  in  precursor  cells.  It  is  also  secreted  by
exocrine  epithelial  cells  (found  in  the  saliva,  gastric  acid,
bile  and  breast  milk).  TC  I  binds  to  70%  of  cobalamin  and
protects  it  from  the  acid  environment  of  the  digestive  sys-
tem.  However,  when  it  binds  to  cobalamin  at  other  sites,
it  neutralizes  the  function  of  cobalamin.
 Transcobalamin  II  (TC  II).  TC  II  is  synthesized  by  epithe-
lial  and  endothelial  cells,  monocytes  and  ﬁbroblasts.  It
binds  around  30%  of  circulating  cobalamin  and  is  its  only
real  carrier,  transporting  it  to  target  cells  where  it  will  be
used.
 Transcobalamin  III  (TC  III).  TC  III  is  found  in  neutrophils;
it  has  no  known  action.  TC  III  levels  are  elevated  in
polycythaemia  vera  and  other  chronic  myeloproliferative
malignancies.21
Cobalamin  is  absorbed  in  the  digestive  system  in  three
tages:
 Stomach.  Cobalamin  in  food  is  bound  to  proteins  fromPregnant  women  600  2.6
Breastfeeding  women  500  2.6
Children  and  adolescents  50--200  0.4--1.8
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 Duodenum  and  jejunum.  The  alkalizing  action  of  the
pancreatic  juices  together  with  the  action  of  the  pancre-
atic  enzymes  (tripsin,  chymotrypsin  and  elastase)  degrade
the  TC  I  and  release  the  cobalamin,  which  is  now  taken  up
by  the  intrinsic  factor  (IF).  IF  is  produced  by  the  parietal
cells  of  the  fundus  and  cardia  of  the  stomach.  It  protect
the  cobalamin  and  carries  it  to  the  cubilin  in  the  ileum.
 Ileum.  The  IF-cobalamin  complex  binds  to  cubilin  and
is  taken  up  into  the  enterocyte  by  means  of  a  calcium-
dependent  passive  transport  mechanism.
Once  inside  the  enterocyte,  the  IF-cobalamin  complex
s  engulfed  by  lysosomes,  where  enzymes  degrade  the  IF
nd  release  the  cobalamin.  The  cobalamin  then  exits  to  the
ytoplasm,  where  it  is  taken  up  by  TC  II.  In  this  way,  the  TC
I/cobalamin  complex  exits  the  enterocyte  via  its  basolat-
ral  membrane  and  is  released  into  the  systemic  circulation
r  the  enterohepatic  cycle  (liver,  bile  acids,  intestine).  In
he  systemic  circulation,  cobalamin  can  bind  to  any  of  the
 aforementioned  cobalophilins.  TC  II  transports  it  to  the
ells  where  it  will  be  used.  It  is  taken  up  into  the  cells
y  binding  to  either  TC  II  receptors  (TC  IIR)  or  megalin
a  protein).  Cobalamin  is  taken  up  by  cells  by  means  of
lathrin-mediated  endocytosis,  the  same  intracellular  trans-
ort  mechanisms  used  in  folic  acid  uptake.  Once  inside  the
ells,  TC  II  is  degraded,  thus  releasing  the  cobalamin.13,15,22
Excess  intracellular  cobalamin  can  pass  into  the  blood
tream,  from  where  it  is  ﬁltered  through  the  glomerulus  and
liminated  in  the  urine.19In  humans,  the  2  active  forms  of
obalamin  involved  in  biological  functions  are:
 Methycobalamin.  A  co-enzyme  of  methionine  synthase
(also  known  as  methyltetrahydrofolate-homocysteine
methyltransferase),  an  enzyme  involved  in  methionine
and  tetrahydrofolate  synthesis  from  methyltetrahydro-
folate  and  homocysteine.  This  is  where  the  folate  and
cobalamin  metabolism  pathways  meet,  and  it  is  some-
times  called  the  ‘‘folate  trap.’’
 Adenosylcobalamin.  A  co-enzyme  of  methylmalonyl-CoA,
an  enzyme  involved  in  the  production  of  succinic  acid  from
methylmalonyl  acid  (accumulation  of  which  causes  neu-
ropathy).  Succinate  plays  a  role  in  the  Krebs  cycle,  an
energy-releasing  pathway.
Two  hypotheses  have  been  developed  to  explain  how
obalamin-deﬁciency  anaemia  is  in  fact  caused  by  functional
olate  deﬁciency.23,24
 Methyltetrahydrofolate  trapping,  or  the  ‘‘folate  trap’’.
Without  cobalamin,  methyltetrahydrofolate  cannot  be
demethylated  by  methionine  synthesis.  Remember,
methyltetrahydrofolate  cannot  be  polyglutamised,  and
therefore  cannot  be  ‘‘anchored’’  to  the  cell.  This  means
that  it  can  escape  without  being  used.
 Formate  deﬁciency.  When  tetrahydrofolate  is  depleted
(as  described  above),  stored  methyltetrahydrofolate  can-
not  be  converted  into  polyglutamisable  formate-mediated
formyltetrahydrofolate,  which  is  another  functional  form
of  folate  (in  addition  to  the  oft-mentioned  tetrahydrofo-
late)  used  in  purine  synthesis.
c
f
d
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In  addition  to  the  foregoing  hypotheses,  cobalamin
nd  folic  acid  metabolization  share  another  common
eature:  they  both  require  methylenetetrahydrofolate  (a
roduct  of  tetrahydrofolate)  and  dUMP  to  form  thymidy-
ate  synthase-mediated  thymidylate  and  dihydrofolate.  For
he  reasons  stated  above,  tetrahydrofolate  cannot  occur
ithout  cobalamin,  and  without  tetrahydrofolate,  neither
ethylenetetrahydrofolate  nor  its  product,  thymidylate,
an  occur.23,24
athophysiology of megaloblastic anemia
he  pathophysiology  of  this  group  of  anaemias  has  its  origins
n  ineffective  erythropoiesis  secondary  to  intramedullary
poptosis  of  hematopoietic  precursor  cells.  This,  in  turn,
s  caused  by  DNA  synthesis  abnormalities.
Remember,  both  folate  and  cobalamin  deﬁciency  ulti-
ately  lead  to  thymidylate  deﬁciency.  DNA  contains  2
urine  bases  (adenine  and  guanine)  and  2  pyrimidine  bases
thymine  and  cytosine).8,25
When  there  is  insufﬁcient  thymidylate  or  thymine  at  the
osition  in  the  DNA  strand  where  these  nitrogenous  bases
hould  occur,  they  are  replaced  by  uracil.  This  happens  pri-
arily  when  uracil  is  incorporated  at  2  similar  positions
n  opposite  strands.  When  uracil  is  incorporated  into  what
hould  be  a purely  DNA  structure,  the  repair  enzymes  detect
he  error  and  try  to  correct  it,  albeit  unsuccessfully.  As  a
esult,  ﬁrst  1,  then  both  DNA  strands  are  destroyed,  with
he  resulting  p53-mediated  cellular  apoptosis.8,25,26
This  in  turn  leads  to  asynchronous  maturation  between
he  nucleus  and  the  cytoplasm.  The  latter,  devoid  of  DNA,
oes  not  fully  mature,  and  the  former,  in  which  RNA  pro-
uction  continues  and  haemoglobin  synthesis  is  unaltered,
ature  at  the  normal  rate.8,9,25,26
tiology of megaloblastic anemia
olic  acid  deﬁciency  is  usually  due  to  low  folate  content
n  the  diet,  or  to  an  imbalance  between  folate  demand
nd  intake.  Cobalamin  deﬁciency  is  usually  caused  by
oor  absorption  of  this  vitamin  in  the  digestive  tract  (see
able  2).25,27
linical picture
he  clinical  spectrum  of  megaloblastic  anaemia  is  shown
n  Table  3,  where  the  minor  differences  between  the
linical  manifestations  of  megaloblastic  anaemia  caused
y  folate  deﬁciency  and  by  cobalamin  deﬁciency  are
ighlighted.6,25,28
athophysiology  of  neurological  changes
obalamin  deﬁciency  causes  subacute  combined  degenera-
ion  of  the  posterior  and  lateral  grey  column  of  the  spinal
ord  due  to  methionine  deﬁciency.  Methionine  is  needed
or  the  production  of  myelin.  Myelin  deﬁciency  causes
emyelination  and  gliosis  of  the  grey  column,  which  is  fur-
her  aggravated  by  the  neurotoxicity  of  methylmalonic  acid.
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Table  2  Causes  of  folic  acid  and  cobalamin  deﬁciency.
Causes  of  folic  acid  deﬁciency  Causes  of  cobalamin  deﬁciency
Dietary  deﬁciency  Dietary  deﬁciency
(a) Malnutrition
(b)  Elderly  patients
(c)  Alcohol  intake
(d)  Goat’s  milk  intake
(a)  Strict  vegetarians
Malabsorption  Absorption  problems
(a) Intestinal  disorders.  Tropical  sprue,  celiac  disease,
Crohn’s  disease,  extensive  small  bowel  resection,
leukemic/lymphomatous  inﬁltration,  Whipple’s  disease,
scleroderma,  amyloidosis,  diabetes  mellitus.
(b)  Familial  malabsorption.  Intestinal  conjugase  deﬁciency
Very rare  disease.  Inheritance:  autosomal  recessive  Causes
mental  retardation,  convulsions,  ataxia  or  athetosis.
(a)  Gastric  disorders.  Pernicious  anaemia,  gastritis,
achlorhydria  or  hypochlorhydria  (age,  atrophic  gastritis,
proton  pump  inhibitors  or  H2  antagonists),  Helicobacter  pylori
infection,  total  or  partial  gastrectomy,  Zollinger--Ellison
syndrome.
(b) Intestinal  disorders.  Extensive  ileal  resection,  regional
ileitis, leukemic/lymphomatous  inﬁltration,  tuberculosis,
Crohn’s  disease,  postradiation  ileitis,  tropical  sprue  or  celiac
disease,  scleroderma,  amyloidosis,  blind  loop  syndrome  with
bacterial  overgrowth,  Diphyllobothrium  latum,  Giardia
lamblia,  Strongiloides  stercoralis,  use  of  drugs  that  diminish
absorption:  cholestyramine,  metformin,  colchicine.
(c) Pancreatic  diseases.  Hereditary  chronic  pancreatitis,
Imerslund--Grasbeck  disease  (cubilin  deﬁciency).
Genetic defects  Genetic  defects
(a) Enzyme  defects.  Dihydrofolate  reductase,
methylenetetrahydrofolate  and  glutamate
formiminotransferase  deﬁciencies.
(a)  Transcobalamin  II  deﬁciency.
(b)  Functional  impairment  of  transcobalamin  II.
(c) Haptocorrin  or  transcobalamin  I  deﬁciency.
(d) Homocystinuria.
(e)  Methylmalonic  acidaemia.
(f) Methylenetetrahydrofolate  deﬁciency.
(g) Cobalamin  mutation.
Increased requirements
(a)  Pregnancy  and  breastfeeding.
(b) Chronic  haemolytic  anaemia.
(c) Chronic  exfoliative  dermatitis.
Drug  therapies
(a)  Trimethoprim.  Inhibits  dihydrofolate  reductase.
(b) Pyrimethamine.  Inhibits  dihydrofolate  reductase.
(c) Methotrexate.  Inhibits  dihydrofolate  reductase.
(d)  Phenytoin  and  valproic  acid.  Reduce  absorption  and
change  its  metabolism.
Table  3  Clinical  manifestation  of  megaloblastic  anaemia.
Clinical  manifestation  of  megaloblastic  anaemia
Folate/cobalamin  deﬁciency
(a)  Interview.  Anaemic  syndrome,  sometimes  tissue  hypoxia.
(b) Physical  examination.  Pale  yellow  colour  (pallor/icterus),  Hunter’s  glossitis,  nail  pigmentation,  change  of  hair  colour,
splenomegaly  (10--15%).
Cobalamin  deﬁciency
(a)  Neurological
(1)  Symptoms.  Loss  of  joint  position  sense  in  the  second  toe,  loss  of  vibration  sense  in  toes  and  ﬁngers,  paraesthesia,
hypoesthesia,  tingling,  gait  abnormalities,  loss  of  coordination,  muscle  weakness,  spasticity,  optic  neuropathy,  urinary  and
faecal incontinence,  erectile  dysfunction,  dementia,  memory  loss.  Neuropathy  is  symmetric,  and  mainly  affects  the  lower
extremities.
(2) Signs.  Positive  for  Romberg’s  test,  Lhermitte’s  sign,  Babinski  reﬂex,  spasticity,  hyporeﬂexia,  clonus.
(b) Osteoporosis
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levation  of  tumour  necrosis  factor  alpha  and  epidermal
rowth  factor  also  contribute  to  neurological  changes.28,29
lood picture
ll  types  of  megaloblastic  anaemia,  whether  caused  by  folic
cid  or  cobalamin  deﬁciency,  present  the  following  labora-
ory  ﬁndings.25
 Flow  cytometry.  In  addition  to  anaemia,  macrocytosis
is  found  in  75%  of  cases  (note  that  in  25%  of  patients
mean  corpuscular  volume  [MCV]  is  normal,  above  all  in
cases  with  concurrent  iron  deﬁciency  or  thalassemia).
Macrocytosis  can  be  classiﬁed  as  mild  (100--105  fL),  mod-
erate  (106--115  fL)  or  severe  (>116  fL).  Another  ﬁnding
is  increased  blood  cell  distribution  width.  In  some  cases
(associated  with  severe,  chronic  folic  acid  or  cobalamin
deﬁciency)  varying  degrees  of  leukoneutropaenia  and
thrombocytopenia  can  be  present  (usually  mild  to  mod-
erate,  but  occasionally  severe).6,7,25 Peripheral  blood  samples.  The  most  notable  ﬁndings
are  macrocytosis  and  hypersegmented  neutrophils.  From
a  morphological  point  of  view,  these  abnormalities
together,  while  not  pathognomonic,  are  highly  suggestive
Table  4  Speciﬁc  diagnostic  tests  for  folate  and  cobalamin  deﬁci
Laboratory  studies  and  diagnostic  ranges  Si
Serum  folate
<2  ng/mL  is  diagnostic
>4  ng/mL  rules  out  deﬁciency
2--4 ng/mL  =  quantify  methylmalonic  acid  and  homocysteine
Fa
dr
in
Fa
Intra-enterocyte  folate  (methyltetrahydrofolate  [MTHF]  and  form
<100--160  mg/L  =  deﬁciency
63%  of  patients  with  cobalamin  deﬁciency  have  low
erythrocyte  folate  levels.
Compared  with  serum  folate,  less  likely  to  alter  due  to
transient  variations  such  as  dietary  changes.
Fa
dr
in
Fa
Serum cobalamin
<200  pg/mL  diagnostic  of  deﬁciency
>300  pg/mL  rules  out  deﬁciency  in  95%  of  cases
200--300  pg/mL  =  quantify  methylmalonic  acid  and
homocysteine
Intra-individual  variation:  up  to  23%
Fa
an
ap
no
co
Methylmalonic  acid  (MMA)
Normal:  70--270  mmol/L
Intra-individual  variation:  up  to  23%
Usually  elevated  with  comorbid  cobalamin  deﬁciency
Fa
Fa
Homocysteine
Normal: 5--14  mmol/L
Intra-individual  variation:  17%
Usually  elevated  with  comorbid  cobalamin  and  folate
deﬁciency
Fa
ch
sy
Elevated MMA and homocysteine: cobalamin deﬁciency (sensitivity: 94
Normal MMA and homocysteine: rules out deﬁciency of both vitamins.
Normal MMA and elevated homocysteine: folate deﬁciency (sensitivity:H.B.  Castellanos-Sinco  et  al.
of  megaloblastic  anaemia.  Hypersegmented  neutrophils
refers  to  the  presence  of  >5%  of  neutrophils  with  5  seg-
ments,  or  >1%  with  6  segments.  Other  ﬁndings  include
anisocytosis,  basophilic  stippling,  Howell--Jolly  bodies,
and  giant  hypersegmented  granulocytes.7,25
 Reticulocyte  count  (percentage  and  absolute).  Supravi-
tal  staining  shows  reticulopaenia.6,25
 Biochemistry  tests.  These  show  ineffective
haematopoiesis,  characterized  by  intramedullary
haemolysis,  such  as:  elevated  indirect  bilirubin  and
lactate  dehydrogenase  (LDH).  A  certain  amount  of
intravascular  haemolysis  can  also  be  found,  with  reduced
haptoglobin  levels.6,25
 Bone  marrow  aspiration/bone  biopsy.  Megaloblastic
changes  occur  in  the  morphology  of  the  erythrocytic  and
myelocytic  series.  Red  cell  precursors  (mainly  orthochro-
matic  erythroblasts)  are  enlarged  and  nucleus/cytoplasm
maturation  is  asynchronous.  This  latter  is  character-
ized  by  immature  nuclei  (larger,  with  open  or  lax
chromatin)  and  mature  cytoplasm  (with  its  normal  red
hemoglobulinised  colour).  Megaloblasts  in  the  myelo-
cytic  series  manifest  as  larger  precursors  (mainly  bands).
A  less  common  ﬁnding  is  the  presence  of  hyperdiploid
megakaryocytes.6,7,25
ency.
tuations  affecting  results
lsely  low:  Pregnancy,  alcohol  consumption,  anti-seizure
ugs,  temporarily  (a  few  days)  deﬁcient  diet  (with  normal
tra-enterocyte  folate).
lsely  elevated:  Single  intake  of  folate-rich  food.
yltetrahydrofolate  (FTHF])
lsely  low:  Pregnancy,  alcohol  consumption,  anti-seizure
ugs,  temporarily  (a  few  days)  deﬁcient  diet  (with  normal
tra-enterocyte  folate).
lsely  elevated:  Single  intake  of  folate-rich  food.
lsely  low:  Pregnancy,  folate  deﬁciency,  HIV/Aids,
ti-seizure  drugs,  multiply  myeloma,  hairy  cell  leukaemia,
lastic  anaemia,  myelodysplastic  syndromes,  paroxysmal
cturnal  haemoglobinuria,  Gaucher’s  disease,  oral
ntraceptives,  idiopathic  origin,  laboratory  error.
lsely  elevated:  Kidney  failure,  methylmalonic  acidaemia.
lsely  low:  Use  of  antibiotics.
lsely  elevated:  Hereditary  hyperhomocysteinaemia:
anges  in  methyl-THFR,  cystathionine  beta-synthase,  betaine
nthesis.
%, speciﬁcity: 99%).
 86%, speciﬁcity: 99%).
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Cyanocobalamin
1000 µg/day, intramuscular, for 2 weeks.
Continue with 1000 μg/week
Continue therapy until…
Response time
Cyanoco
balamin
1,000 to 2,000 μg/day
p.o. until blood
levels normalize
Continue with
1,000 µg/day p.o.
Folic acid
1-2 days 3-4 days 
- Reduction of serum iron,
  indirect bilirubin and
  lactate dehydrogenase.
- Normal haemopoiesis
- Reticulocytosis
- Haemoglobin starts
   to increase.
- Reduction of mean
  corpuscular volume
-Disappearance of
  hypersegmented
  neutrophilsados
- Resolution of
  anaemia
- Resolution of
neuropathy
10 days 14 days 2 months 3-12 months
- Blood count normalizes
- Underlying condition resolves
  (if no underlying condition,
  continue indefinitely).
1 to 5 mg/day p.o.
for 3 to 4 months
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hFigure  2  Pharmacological  man
•  Other  markers.  Serum  iron,  ferritin  and  transferrin  levels
are  elevated.6,25
Diagnosis
Clinical  presentation  supported  by  common  laboratory  test
ﬁndings  usually  strongly  suggest  megaloblastic  anaemia.
For  speciﬁc  diagnosis,  however,  folic  acid  and  cobalamin
levels  must  be  quantiﬁed.  Sometimes,  quantiﬁcation  of
intermediary  metabolites  such  as  methylmalonic  acid  and
homocysteine  may  also  be  required.  Table  4  shows  the  ref-
erence  ranges  and  interpretation  of  these  studies,  together
with  a  list  of  situation  that  can  affect  these  results.6,7,25,30
It  is  important  to  bear  in  mind  the  possibility  of  sub-
clinical  cobalamin  deﬁciency,  found  in  10--20%  of  geriatric
patients.  In  this  condition,  serum  cobalamin  levels  are
slightly  low,  and  AMM  and  homocysteine  levels  slightly
elevated.  In  some  cases,  serum  cobalamin,  AMM  and  homo-
cysteine  levels  can  be  within  normal  ranges.  In  the  absence
of  clinical  changes,  and  at  times  even  in  the  absence  of
abnormal  laboratory  ﬁndings,  this  type  of  anaemia  can  only
be  diagnosed  on  the  basis  of  high  clinical  suspicion.25,30
Treatment
Folic  acid  deﬁciencyBefore  starting  treatment  for  megaloblastic  anaemia  due  to
folic  acid  deﬁciency,  it  is  important  to  ascertain  the  absence
of  concomitant  cobalamin  deﬁciency,  and  even  to  establish
C
I
sent  of  megaloblastic  anaemia.
hat  cobalamin  deﬁciency  is  not,  in  fact,  the  sole  patho-
enesis.  When  folates  are  given  to  a  patient  with  cobalamin
eﬁciency  as  the  sole  cause  of  the  anaemia,  or  when  both
olic  acid  and  cobalamin  deﬁciency  are  involved,  the  blood
icture  will  improve  but  neurological  manifestations  will
orsen.  High-dose,  oral  supplements  should  be  given.  See
ig.  2  for  an  overview  of  pharmacological  management.11,23
obalamin  deﬁciency
s  in  the  case  of  folate  deﬁciency,  cobalamin  deﬁciency
herapy  should  continue  until  blood  levels  return  to  nor-
al,  or  the  underlying  condition  is  resolved.  The  best
oute  of  administration  is  intramuscular.  Excess  cobalamin  is
xcreted  in  the  urine.  Recent  studies  suggest  that  oral  cobal-
min  is  a  safe  and  effective  alternative,  even  in  patients
ith  low  intrinsic  factor  levels.  In  patients  that  respond  well
o  oral  cobalamin,  treatment  should  continue  indeﬁnitely  at
 dose  of  1000  mcg/day  9  Fig.  2).30--32
linical  course
nitial  response,  in  the  form  of  normalization  of
aematopoiesis,  is  rapid.  Reversal  of  neurological  changes,
owever,  takes  longer  (Fig.  2).8,12,25obalamin deﬁciency prophylaxis
n  certain  patients,  cobalamin  supplements  should  be  con-
idered  as  part  of  routine  clinical  practice.
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egetarians
trict  vegetarians  should  receive  between  2  and  6  mcg/day
f  oral  supplement.  Pregnant  vegetarians  (strict  or  not)  that
lso  intend  to  breastfeed  need  an  even  higher  dose,  as  their
ffspring  are  at  high  risk  of  presenting  severe  cobalamin
eﬁciency.33,34
atients  with  prior  gastric  surgery
atients  with  prior  partial  gastrectomy  or  gastric  bypass
urgery  are  at  high  risk  for  subclinical  cobalamin  deﬁciency
r  deﬁciency  associated  with  impaired  absorption  of  cobal-
min.  These  patients  should  take  1000  mcg/day  cobalamin
efore  meals.35,36
lderly  patients
n  the  absence  of  well-designed  studies  investigating  this
opic,  the  beneﬁt  of  routine  administration  of  cobalamin
upplements  is  unclear.  In  special  circumstances,  cobalamin
evels  can  be  quantiﬁed.6,37
xposure  to  nitrous  oxide
itrous  oxide  is  known  to  inactivate  cobalamin.  For  this  rea-
on,  untreated  or  undiagnosed  clinical  cobalamin  in  patients
cheduled  for  surgery  using  nitrous  oxide  may  present  rapid
europsychiatric  deterioration.  The  pre-operative  workup
f  these  patients,  therefore,  should  include  cobalamin  tests
r  ﬂow  cytometry,  and  deﬁciency  should  be  fully  resolved
efore  surgery.  It  is  also  important  to  bear  in  mind  that
itrous  oxide  is  sometimes  used  as  a  recreational  drug,
f  chronic,  this  abuse  can  cause  serious  neuropsychiatric
isorders,  even  when  not  associated  with  vitamin  B12
eﬁciency.38,39
onclusions
he  aim  of  this  review  has  been  to  outline  the  essential  infor-
ation  needed  for  the  correct  management  of  patients  with
egaloblastic  anaemia.  Cases  not  associated  with  a  simple
ietary  deﬁciency,  such  as  intestinal  absorption  disorders  or
ellular  abnormalities,  merit  particular  attention,  as  physi-
ians  not  familiar  with  this  aetiology  will  often  have  trouble
iagnosing  and  treating  these  patients.
Pharmacological  management  appears  to  be  straightfor-
ard.  It  is  based  supplementing  deﬁcits  and  building  up
ody  reserves.  Follow-up  of  the  latter  is  the  key  to  a  suc-
essful  outcome  in  these  patients.  It  is  also  important  to
onsider  the  patient’s  dietary  habits.  Dietary  advice  should
e  given  in  the  absence  of  an  underlying  medical  condition
reventing  absorption  of  nutrients.  In  these  cases,  alterna-
ive  strategies  should  be  implemented  to  cover  nutritional
equirements.
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